Patents by Inventor Herma C. Neyndorff

Herma C. Neyndorff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Photodynamic therapy for the treatment of acne
    Publication number: 20100056982
    Abstract: The present method involves the photodynamic treatment of acne vulgaris. The method involves the topical administration of a photosensitizer composition comprising hydrophobic green porphyrins such as lemuteporfin, polyethylene glycol and skin penetration enhancers such as oleyl alcohol and TRANSCUTOL™ to acne-affected skin and subsequent exposure of that skin to energy of a wavelength of activating the photosensitizer.
    Type: Application
    Filed: February 4, 2005
    Publication date: March 4, 2010
    Applicant: QLT Inc.
    Inventors: Alain H. Curaudeau, Herma C. Neyndorff, Jinj-Song Tao, Morgan Chun Lam, Patrick Mark Curry, Valery Rubinchik, David W.C. Hunt
  • Photodynamic Therapy For The Treatment Of Hyperactive Sebaceous Gland Disorders Using Topically Applied Hydrophobic Green Porphyrins
    Publication number: 20080096857
    Abstract: The present method involves the photodynamic treatment of hyperactive gland disorders. The method involves the topical administration of a photosensitizer composition comprising hydrophobic and/or lipophilic green porphyrins such as lemuteporfin, polyethylene glycol and skin penetration enhancers such as oleyl alcohol and TRANSCUTOL™ to affected skin and subsequent exposure of that skin to energy of a wavelength capable of activating the photosensitizer.
    Type: Application
    Filed: February 8, 2005
    Publication date: April 24, 2008
    Applicant: QLT Inc.
    Inventors: Alain H. Curaudeau, Herma C. Neyndorff, Jing-Song Tao, Julia G. Levy, David W.C. Hunt, Morgan Chun Lam, Patrick Mark Curry, Valery Rubinchik
  • Photodynamic therapy for the treatment of non-melanoma skin cancer
    Publication number: 20040110731
    Abstract: The present invention relates to a method of treating non-melanoma skin cancer comprising: (a) intravenously administering a porphyrin based photosensitizer to a subject with non-melanoma skin cancer; (b) irradiating one or more tumors and a circumferential peritumoral margin of at least 1 mm with a light at a wavelength absorbed by said photosensitzer; wherein the irradiating step delivers a light dose of 180 J/cm2. It has been found that the above treatment gives extremely good efficacy while having a surprisingly good cosmetic outcome.
    Type: Application
    Filed: December 4, 2002
    Publication date: June 10, 2004
    Inventors: Agnes H. Chan, Herma C. Neyndorff
  • Method for inactivating pathogens in compositions containing cells and plasma using photoactive compounds and plasma protein reduction
    Patent number: 5597722
    Abstract: The present invention provides a method for inactivating pathogens in a body fluid, such as plasma, red cells, platelets, leukocytes, and bone marrow. The present invention minimizes adverse effects caused by the photosensitive agents while retaining the disinfecting activity of such agents and processes. Pursuant to the present invention, prior to irradiating a body fluid including a photoactive drug, the extracellular fluid, which in the case of blood components includes plasma proteins is at least substantially reduced. Additionally, after the irradiation process, the resultant body fluid is prevented from contacting additional extracellular fluid, e.g., plasma proteins, for a predefined period.
    Type: Grant
    Filed: July 13, 1994
    Date of Patent: January 28, 1997
    Assignee: Baxter International Inc.
    Inventors: John Chapman, Patricia M. Logan, Herma C. Neyndorff, Janice North
  • Method for inactivating pathogens in erythrocytes using photoactive compounds and plasma protein reduction
    Patent number: 5360734
    Abstract: The present invention provides a method for inactivating pathogens in a body fluid, such as plasma, red cells, platelets, leukocytes, and bone marrow. The present invention minimizes adverse effects caused by the photosensitive agents while retaining the disinfecting activity of such agents and processes. Pursuant to the present invention, prior to irradiating a body fluid including a photoactive drug, the extracellular fluid, which in the case of blood components includes plasma proteins is at least substantially reduced. Additionally, after the irradiation process, the resultant body fluid is prevented from contacting additional extracellular fluid, e.g., plasma proteins, for a predefined period.
    Type: Grant
    Filed: January 28, 1993
    Date of Patent: November 1, 1994
    Assignees: Baxter International, Inc., Quadra Logic Technologies, Inc.
    Inventors: John Chapman, Patricia M. Logan, Herma C. Neyndorff, Janice North